These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 34359303)

  • 1. Anaplastic Lymphoma Kinase- and CD30-Positive Anaplastic Large-Cell Lymphoma of the External Auditory Canal.
    Chen SL; Chan KC
    Diagnostics (Basel); 2021 Jul; 11(7):. PubMed ID: 34359303
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complete response in a critically ill patient with ALK-negative anaplastic large cell lymphoma treated with single agent brentuximab-vedotin.
    Oregel KZ; Everett E; Zhang X; Nagaraj G
    Expert Rev Anticancer Ther; 2016; 16(3):279-83. PubMed ID: 26809026
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brentuximab vedotin for refractory anaplastic lymphoma kinase-negative anaplastic large cell lymphoma in leukemic phase with
    Yamashita Y; Hori Y; Kosako H; Oiwa T; Warigaya K; Mushino T; Murata S; Fujimoto M; Nishikawa A; Murata SI; Sonoki T; Tamura S
    Hematol Rep; 2020 May; 12(1):8368. PubMed ID: 32499905
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination therapy with brentuximab vedotin and cisplatin/cytarabine in a patient with primarily refractory anaplastic lymphoma kinase positive anaplastic large cell lymphoma.
    Heidegger S; Beer AJ; Geissinger E; Rosenwald A; Peschel C; Ringshausen I; Keller U
    Onco Targets Ther; 2014; 7():1123-7. PubMed ID: 25018638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Brentuximab vedotin and crizotinib in anaplastic large-cell lymphoma.
    Foyil KV; Bartlett NL
    Cancer J; 2012; 18(5):450-6. PubMed ID: 23006951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anaplastic Lymphoma Kinase Immunocytochemistry in Fine Needle Aspiration Diagnosis of Anaplastic Large-cell Lymphoma.
    Ramteke P; Chitragar S; Singh A; Mallick S; Mathur SR; Jain D; Iyer VK
    J Cytol; 2018; 35(1):37-40. PubMed ID: 29403168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategy for Pediatric Patients with Relapsed or Refractory Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma: A Review.
    Noguchi K; Ikawa Y
    Cancers (Basel); 2023 Dec; 15(24):. PubMed ID: 38136278
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anaplastic lymphoma kinase-positive anaplastic large cell lymphoma: current and future perspectives in adult and paediatric disease.
    Eyre TA; Khan D; Hall GW; Collins GP
    Eur J Haematol; 2014 Dec; 93(6):455-68. PubMed ID: 24766435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Primary bone anaplastic lymphoma kinase positive anaplastic large-cell lymphoma: A case report and review of the literature.
    Zheng W; Yin QQ; Hui TC; Wu WH; Wu QQ; Huang HJ; Chen MJ; Yan R; Huang YC; Pan HY
    World J Clin Cases; 2021 May; 9(14):3403-3410. PubMed ID: 34002151
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of CD30 expression after treatment with brentuximab vedotin in a patient with anaplastic large cell lymphoma: a novel finding.
    Al-Rohil RN; Torres-Cabala CA; Patel A; Tetzlaff MT; Ivan D; Nagarajan P; Curry JL; Miranda RN; Duvic M; Prieto VG; Aung PP
    J Cutan Pathol; 2016 Dec; 43(12):1161-1166. PubMed ID: 27531242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic and primary cutaneous anaplastic large cell lymphoma: Clinical features, morphological spectrum, and immunohistochemical profile.
    Kwatra KS; Paul PAM; Calton N; John JM; Cotelingam JD
    South Asian J Cancer; 2017; 6(3):129-131. PubMed ID: 28975123
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD30-Positive Anaplastic Lymphoma Kinase-Negative Systemic Anaplastic Large-Cell Lymphoma in a 9-Year-Old Boy.
    Kim JE; Oh EH; Ro YS; Ko JY
    Ann Dermatol; 2016 Jun; 28(3):371-4. PubMed ID: 27274637
    [TBL] [Abstract][Full Text] [Related]  

  • 13. When Lymphoma Strikes the Pancreas: A Rare Presentation of Systemic Anaplastic Lymphoma Kinase-Negative Anaplastic Large Cell Lymphoma in a Human Immunodeficiency Virus-Positive Patient.
    Huang HH; Qing X
    J Hematol; 2023 Oct; 12(5):236-242. PubMed ID: 37936974
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brentuximab vedotin in anaplastic large cell lymphoma.
    Skarbnik AP; Smith MR
    Expert Opin Biol Ther; 2012 May; 12(5):633-9. PubMed ID: 22449148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the t(2;5)(p23;q35) translocation by reverse transcription-polymerase chain reaction in CD30+ anaplastic large-cell lymphomas, in other non-Hodgkin's lymphomas of T-cell phenotype, and in Hodgkin's disease.
    Wellmann A; Otsuki T; Vogelbruch M; Clark HM; Jaffe ES; Raffeld M
    Blood; 1995 Sep; 86(6):2321-8. PubMed ID: 7662979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The biology and management of systemic anaplastic large cell lymphoma.
    Hapgood G; Savage KJ
    Blood; 2015 Jul; 126(1):17-25. PubMed ID: 25869285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary Cutaneous CD30+/ALK- ALCL with Transition into sALCL: Favourable Response after Systemic Administration with Brentuximab Vedotin! Unique Presentation in a Bulgarian Patient!
    Popova TN; Radinov A; Stavrov K; Temelkova I; Terziev I; Lozev I; Lukanova D; Mangarov H; Wollina U; Tchernev G
    Open Access Maced J Med Sci; 2018 Jul; 6(7):1275-1277. PubMed ID: 30087736
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase I clinical study of brentuximab vedotin (SGN-35) involving children with recurrent or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large cell lymphoma: rationale, design and methods of BV-HLALCL study: study protocol.
    Sekimizu M; Iguchi A; Mori T; Koga Y; Kada A; Saito AM; Horibe K
    BMC Cancer; 2018 Feb; 18(1):122. PubMed ID: 29390984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ; Govi S; Pileri SA; Savage KJ
    Crit Rev Oncol Hematol; 2013 Feb; 85(2):206-15. PubMed ID: 22789917
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Among diffuse large B-cell lymphomas, T-cell-rich/histiocyte-rich BCL and CD30+ anaplastic B-cell subtypes exhibit distinct clinical features.
    Maes B; Anastasopoulou A; Kluin-Nelemans JC; Teodorovic I; Achten R; Carbone A; De Wolf-Peeters C;
    Ann Oncol; 2001 Jun; 12(6):853-8. PubMed ID: 11484964
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.